REVIVA PHARMACEUTICALS

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 Nov 2024 17:25:00 By Nasdaq GlobeNewswire

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

12 Nov 2024 08:00:02 By Nasdaq GlobeNewswire

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the UBS Global Healthcare Conference

31 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

08 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

02 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

26 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

09 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

04 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024

27 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

21 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights

14 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis

06 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

09 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

29 May 2024 16:45:48 By Nasdaq GlobeNewswire

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

28 May 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the BIO International Convention

21 May 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

15 May 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

14 May 2024 08:00:00 By Nasdaq GlobeNewswire

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

13 May 2024 08:00:00 By Nasdaq GlobeNewswire